Claims for Patent: 9,408,864

Summary for Patent: 9,408,864

Title:	Composition for regenerating normal tissue from fibrotic tissue
Abstract:	The present invention relates to a pharmaceutical composition and a method for regenerating normal tissue from fibrotic tissue, the pharmaceutical composition and the method employing a collagen-reducing substance. In accordance with the present invention, normal tissue can be therapeutically regenerated from fibrotic tissue.
Inventor(s):	Niitsu; Yoshiro (Sapporo, JP), Yoneda; Akihiro (Sapporo, JP), Ishiwatari; Hirotoshi (Sapporo, JP)
Assignee:	Nitto Denko Corporation (Osaka, JP)
Application Number:	13/813,907
Patent Claims:	1. A method comprising identifying a human subject (1) having a fibrotic tissue that continually receives a fibrotic stimulus and (2) for whom regeneration of normal tissue from the fibrotic tissue is needed; and administering an effective amount of a pharmaceutical composition comprising a collagen-reducing substance to the subject, thereby differentiating stem cells into normal tissue cells in the fibrotic tissue and regenerating normal tissue from the fibrotic tissue in the subject while the fibrotic tissue is receiving the fibrotic stimulus. 2. A method comprising identifying a human subject (1) having a fibrotic tissue that continually receives a fibrotic stimulus and (2) for whom regeneration of normal tissue from the fibrotic tissue is needed; reducing collagen in a fibrotic tissue of the subject and/or a step of forming a space for cell growth and differentiation in a fibrotic tissue of the subject; and differentiating stem cells in the fibrotic tissue into normal tissue cells, thereby regenerating normal tissue from the fibrotic tissue while the fibrotic tissue is receiving the fibrotic stimulus. 3. The method according to claim 1, wherein the collagen-reducing substance is selected from the group consisting of a suppressor of collagen production by collagen-producing cells, a promoter of collagen decomposition, and a suppressor of a collagen decomposition inhibitor. 4. The method according to claim 1, wherein the pharmaceutical composition further comprises a targeting agent for collagen-producing cells in fibrotic tissue. 5. The method according to claim 1, wherein the pharmaceutical composition further comprises a retinoid. 6. The method according to claim 3, wherein the suppressor of collagen production by collagen-producing cells is selected from the group consisting of a TGF.beta. inhibitor, HGF or a substance promoting the production thereof, a PPAR.gamma. ligand, an angiotensin inhibitor, a PDGF inhibitor, relaxin or a substance promoting the production thereof, a substance that inhibits the production and secretion of an extracellular matrix component, a cell activity suppressor, a cell growth suppressor, and an apoptosis-inducing substance. 7. The method according to claim 3, wherein the promoter of collagen decomposition is collagenase or a collagenase production promoter. 8. The method according to claim 3, wherein the suppressor of a collagen decomposition inhibitor is a TIMP inhibitor.

Details for Patent 9,408,864

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Smith & Nephew, Inc.	SANTYL	collagenase	Ointment	101995	06/04/1965		2030-08-05